A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants
NCT02109042
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Osteoporosis, Postmenopausal
Interventions
DRUG:
Blosozumab
Sponsor
Eli Lilly and Company